Neurocrine Biosciences (NBIX) Depreciation & Amortization (CF) (2010 - 2026)

Neurocrine Biosciences has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $8.4 million in Q2 2026.

• Depreciation & Amortization (CF) for Q2 2026 came in at $8.4 million, up 33.33% year-over-year; the trailing twelve-month figure through Jun 2026 was $28.7 million (up 16.19% YoY), and the FY2025 annual result was $26.0 million, up 10.64% from the prior year.
• Depreciation & Amortization (CF) grew to $8.4 million in Q2 2026, from $7.2 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $8.4 million in Q2 2026 and troughed at $3.3 million in Q1 2022.
• A 5-year average of $5.4 million and a median of $5.4 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The widest annual swing landed in 2024, when Depreciation & Amortization (CF) soared 52.38%; it then retreated 1.56% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.9 million in 2022, then increased by 25.64% to $4.9 million in 2023, then increased by 26.53% to $6.2 million in 2024, then advanced by 3.23% to $6.4 million in 2025, then jumped by 31.25% to $8.4 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $8.4 million in Q2 2026, $7.2 million in Q1 2026, and $6.4 million in Q4 2025.